Janux Therapeutics, Inc. (JANX) Income Statement
JANX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsJANX revenue and net income
Where JANX's revenue goes
2025Each bar shows an amount and its share of revenue. JANX kept −1,136.2% of revenue as net income.
JANX profit margins
JANX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −5.6% | +5.1% | +92.3% | — |
| Gross profit | −6.5% | −2.5% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
JANX quarterly EPS vs estimates
Janux Therapeutics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.45).
JANX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $10.0M | $10.6M | $8.1M | $8.6M | $3.6M | $380,000 | $0 |
| Cost of revenue | $2.0M | $2.1M | $2.0M | $75.7M | $36.6M | $13,000 | $6,000 |
| Gross profit | $8.0M | $8.5M | $6.1M | $8.6M | $3.6M | −$13,000 | −$6,000 |
| Research & development | $125.9M | $68.4M | $54.9M | $53.4M | $26.2M | $3.0M | $3.0M |
| Sales, general & admin | $41.8M | $41.0M | $26.1M | $22.3M | $10.3M | $1.8M | $772,000 |
| Total operating expenses | $165.6M | $107.4M | $79.1M | $75.7M | $36.6M | $4.8M | $3.8M |
| Operating income | −$157.7M | −$98.8M | −$73.0M | −$67.1M | −$32.9M | −$4.8M | −$3.8M |
| Interest income | $44.0M | $29.9M | $12.5M | $4.0M | $257,000 | $0 | — |
| Interest expense | — | — | — | $4.0M | $370,000 | $206,000 | $233,000 |
| Income before taxes | −$113.6M | −$69.0M | −$58.3M | −$63.1M | −$32.7M | −$6.8M | −$4.0M |
| Income taxes | — | — | $1.8M | −$8.9M | −$113,000 | −$1.5M | $233,000 |
| Net income | −$113.6M | −$69.0M | −$58.3M | −$54.2M | −$32.6M | −$6.8M | −$4.2M |
| EBITDA | −$111.6M | −$66.9M | −$56.3M | −$66.2M | −$32.8M | −$6.6M | −$3.8M |
| EPS (diluted) | −$1.83 | −$1.28 | −$1.34 | −$1.52 | −$2.76 | −$2.63 | −$2.20 |
| Gross margin | 79.7% | 80.5% | 75.8% | 100.0% | 100.0% | −3.4% | — |
| Operating margin | −1,576.7% | −933.6% | −902.9% | −779.0% | −905.4% | −1,274.5% | — |
| Net margin | −1,136.2% | −651.6% | −721.2% | −628.8% | −895.2% | −1,785.3% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.3M | $3.7M | $7.9M | $10.0M | $0 | $0 | $0 | $439,000 | $8.9M | $1.3M | $2.5M | $2.5M |
| Cost of revenue | $0 | $469,000 | $8.9M | $501,000 | $29.2M | $25.1M | $20.8M | $2.4M | $506,000 | $532,000 | $531,000 | $500,000 |
| Gross profit | $10.3M | $3.7M | −$1.1M | $10.0M | −$29.2M | −$25.1M | −$20.8M | −$1.9M | $8.4M | $720,000 | $1.9M | $2.0M |
| Research & development | $31.0M | $26.8M | $31.5M | $34.6M | $34.7M | $25.1M | $20.8M | $18.6M | $14.9M | $14.1M | $12.2M | $11.9M |
| Sales, general & admin | $11.0M | $11.1M | $10.9M | $10.6M | $10.5M | $9.8M | $8.2M | $17.7M | $7.8M | $7.3M | $6.4M | $6.4M |
| Total operating expenses | $42.0M | $37.9M | $42.4M | $45.3M | $15.9M | $9.8M | $8.2M | $33.9M | $22.2M | $20.9M | $18.1M | $17.8M |
| Operating income | −$31.7M | −$34.2M | −$42.4M | −$35.3M | −$45.1M | −$34.9M | −$29.0M | −$35.8M | −$13.8M | −$20.2M | −$16.1M | −$15.8M |
| Interest income | $9.7M | $9.9M | $10.5M | $10.9M | $11.3M | $11.4M | $8.8M | $7.8M | $7.9M | $5.4M | $4.4M | $4.2M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $3.3M | — |
| Income before taxes | −$22.0M | −$24.4M | −$31.9M | −$24.3M | −$33.9M | −$23.5M | −$20.2M | −$28.1M | −$6.0M | −$14.8M | −$11.8M | −$11.6M |
| Income taxes | — | — | — | — | — | — | — | — | — | $488,724 | $953,000 | −$500,000 |
| Net income | −$22.0M | −$24.4M | −$31.9M | −$24.3M | −$33.9M | −$23.5M | −$20.2M | −$28.1M | −$6.0M | −$14.8M | −$11.8M | −$11.6M |
| EBITDA | −$21.5M | −$23.9M | −$31.5M | −$23.8M | −$33.3M | −$23.0M | −$19.7M | −$27.5M | −$5.5M | −$14.2M | −$11.2M | −$11.1M |
| EPS (diluted) | −$0.35 | −$0.39 | −$0.51 | −$0.39 | −$0.55 | −$0.38 | −$0.36 | −$0.51 | −$0.11 | −$0.30 | −$0.25 | −$0.25 |
| Gross margin | 100.0% | 100.0% | −13.5% | 100.0% | — | — | — | −440.8% | 94.3% | 57.5% | 78.4% | 80.1% |
| Operating margin | −308.7% | −916.5% | −538.1% | −352.5% | — | — | — | −8,164.5% | −155.4% | −1,610.3% | −655.7% | −628.2% |
| Net margin | −214.0% | −652.6% | −405.4% | −243.1% | — | — | — | −6,391.6% | −67.0% | −1,178.9% | −477.8% | −459.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in JANX's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
JANX financial results
In fiscal year 2025 (ended December 31, 2025), Janux Therapeutics reported revenue of $10.0 million, down 5.6% from the year before. It had a net loss of $113.6 million, a net profit margin of −1,136.2%. Diluted earnings per share came to −$1.83. Over five years revenue grew at an average rate of 92.3% a year.
See the JANX stock overview for the latest quote and news, or the JANX chart for price history and technical indicators.
JANX income statement FAQ
What is Janux Therapeutics's annual revenue?
Janux Therapeutics reported total revenue of $10.0 million for fiscal year 2025, which ended on December 31, 2025. That was down 5.6% from $10.6 million the previous year.
Is Janux Therapeutics profitable?
No. Janux Therapeutics reported a net loss of $113.6 million in fiscal 2025, a net profit margin of −1,136.2%; its operating margin was −1,576.7%.
What is Janux Therapeutics's gross margin?
Janux Therapeutics's gross margin was 79.7% in fiscal 2025: for every $100 of revenue, Janux Therapeutics kept $80 after the direct cost of its products and services.
How much does Janux Therapeutics spend on research and development?
Janux Therapeutics spent $125.9 million on research and development in fiscal 2025, 1,259.0% of revenue.
How fast is Janux Therapeutics growing?
Revenue grew 92.3% a year on average over the last five fiscal years, from $0.4 million to $10.0 million.
What are Janux Therapeutics's earnings per share?
Janux Therapeutics earned $-1.83 per diluted share in fiscal 2025, compared with $-1.28 a year earlier.
When will Janux Therapeutics report its next earnings?
Janux Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does Janux Therapeutics's fiscal year end?
Janux Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.